PRO-spectives
Building Your Path to Digital Therapeutics Coverage
A practical guide for digital therapeutics manufacturers preparing for payor review: why early cases stall and how to build a coverage path case by case.
Read Now
PRO-spectives
A practical guide for digital therapeutics manufacturers preparing for payor review: why early cases stall and how to build a coverage path case by case.
Read Now
PRO-spectives
Copay programs built for pharmacy claims leave gaps on medical and dual benefit products. See where claims routing and benefit investigation break down.
Read Now
PRO-spectives
What CMS guidance says about AI in health insurance, where AI can speed prior authorization and claims, and the privacy and bias risks to watch.
Read Now
PRO-spectives
Ten facts that make US health policy easier to follow, from how payors write medical policy criteria to how coverage varies across plan types.
Read Now
Trusted by partners spanning industries and specialties.
Success Stories
How dedicated PRO-spectus clinical navigators raised infusion starts from 20% to over 70% of patients and lifted adherence from 10% to a steady 86%.
Read Now
Success Stories
How PRO-spectus virtual field reimbursement managers supported a phased launch across HOPD, inpatient, ASC, and provider group settings to reach profitability.
Read Now
Success Stories
How PRO-spectus virtual field reimbursement managers educated HOPD and ASC sites in the buy and bill channel, cutting open A/R cases 42% in two years.
Read Now
Success Stories
How PRO-spectus education helped a physician-office product expand into hospital outpatient departments and ASCs, driving 400% total volume growth.
Read Now
Success Stories
A manufacturer launched with no payor coverage. See how PRO-spectus payor case management reached 95% of commercial lives and 42 Medicaid states.
Read Now
Success Stories
How PRO-spectus access teams aligned coding, coverage, and payment for a new buy and bill channel, growing volume 190% in Year 3 and 254% in Year 4.
Read Now
Success Stories
How PRO-spectus case management and independent medical review on every denial supported a 100% approval rate in a high-cost oncology launch.
Read Now